BioXcel Therapeutics
BTAI
96 hedge funds and large institutions have $274M invested in BioXcel Therapeutics in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 28 reducing their positions, and 12 closing their positions.
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
21% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 28
3% more funds holding
Funds holding: 93 → 96 (+3)
0.18% less ownership
Funds ownership: 3.11% → 2.93% (-0.18%)
3% less capital invested
Capital invested by funds: $283M → $274M (-$9.19M)
21% less call options, than puts
Call options by funds: $3.46M | Put options by funds: $4.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.86M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.74M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.47M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.01M |
| 5 |
Jane Street
New York
|
+$988K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$26.6M |
| 2 |
Citigroup
New York
|
-$1.13M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$968K |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$609K |
| 5 |
Morgan Stanley
New York
|
-$429K |
BTAI Hedge Fund Activity: Q1 2022 in Review
96 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2022, worth a combined $274M — down 3.2% from $283M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new BTAI positions and 12 closed out — a net gain of 4 holders — while 34 added to existing stakes and 28 trimmed.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $4.86M. The largest seller was AllianceBernstein, cutting an estimated $26.6M.
- 96 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2022, up from 93 in Q4 2021.
- Funds reported $274M of BioXcel Therapeutics stock for Q1 2022, down 3.2% quarter-over-quarter.
- 16 funds opened new BioXcel Therapeutics positions in Q1 2022 and 12 closed out, a net change of +4 holders.
- The largest BioXcel Therapeutics buyer in Q1 2022 was Rubric Capital Management (New York), an estimated $4.86M added.
- The largest BioXcel Therapeutics seller in Q1 2022 was AllianceBernstein, an estimated $26.6M sold.
Based on aggregated 13F filings for Q1 2022.